Exploring a novel drug treatment for osteosarcoma
Drug repurposing targeting immunomodulatory Haem oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Drug repurposing targeting immunomodulatory Haem oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis
Exploring whether a new approach to identifying ependymoma tumours can help support better, more tailored, and potentially less invasive treatment for children with this type of cancer.
Identifying whether children with ALCL, ALK- also harbour other genetic changes in their tumours, and what affect this has on how their cancer progresses. This knowledge can help to guide clinicians about how best to treat children with this rarer sub-form of lymphoma.
Clinical and biological factors associated with relapse and length of survival following relapse in UK neuroblastomas
Establishment of an in vitro model of neuroblastoma initiation using pluripotent stem cell differentiation
Neurosurgically-applied chemotherapy for childhood brain tumours arising in the posterior fossa using a biodegradable paste
GOTHAM - A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in HAemophagocytic lymphohistiocytosis (HLH)/Macrophage activation syndrome (MAS) or relapsed/refractory cancers
The Little Princess Trust Knowledge Bank of Wilms Tumour
Moving Artificial Intelligence of Functional Imaging for children’s tumours into a multi-centre environment through a Clinical Decision Support System